Related Experiment Videos
Particulate contamination in selected parenteral drugs
Abstract:
The particulate contamination of five frequently prescribed drugs was studied. Samples were obtained in a laminar flow workbench according to millipore technique. The dry sample filters were examined with a binocular microscope at 50x and 100x. Particles were sized as to fibers, greater than 100 microns, 51 to 100 microns, 25 to 50 microns, and 10 to 24 microns. The results show the variability of contamination. Particulate counts appear to correlate with the manufacturing process. Bulk powders are highly contaminated, followed by lyophilize powders, then stable solutions. Until the clinical importance is resolved and manufacturing processes improved, in-line filters may be of value in selected patients.
Insights
Particulate contamination varies significantly in commonly prescribed drugs, with bulk powders showing the highest levels. Further research is needed to understand the clinical impact of these drug particulates.
Area of Science:
- Pharmaceutical Science
- Drug Quality Control
- Particulate Matter Analysis
Background:
- Particulate contamination in parenteral drugs is a critical concern for patient safety.
- Previous studies have indicated variability in particulate loads across different drug formulations.
- Understanding the sources and levels of contamination is essential for improving drug manufacturing.
Purpose of the Study:
- To quantify and characterize particulate contamination in five frequently prescribed drugs.
- To investigate the correlation between drug manufacturing processes and observed particulate levels.
- To assess the potential need for in-line filtration in specific patient populations.
Main Methods:
- Samples of five common drugs were collected using sterile techniques in a laminar flow workbench.
- Particulate contamination was assessed on dry sample filters using microscopy at 50x and 100x magnification.
- Particles were categorized by size (fibers, >100 microns, 51-100 microns, 25-50 microns, 10-24 microns).
Main Results:
- Significant variability in particulate contamination was observed among the studied drugs.
- Particulate counts demonstrated a correlation with the drug manufacturing process.
- Bulk powders exhibited the highest contamination, followed by lyophilized powders, and then stable solutions.
Conclusions:
- Drug manufacturing processes directly influence particulate contamination levels.
- In-line filters may offer a protective measure for selected patients pending further clinical significance evaluation.
- Improvements in manufacturing processes are recommended to reduce drug particulate contamination.